ORIC (ORIC Pharmaceuticals) ROCE % : -51.94% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is ORIC Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ORIC Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was -51.94%.

ORIC Pharmaceuticals ROCE % Historical Data

The historical data trend for ORIC Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals ROCE % Chart

ORIC Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-43.00

-26.06

-27.51

-33.68

-47.82

ORIC Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-43.08	-51.63	-40.89	-44.68	-51.94

ORIC Pharmaceuticals ROCE % Calculation

ORIC Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-110.78	/	( ( (247.178 - 15.388)	+	(252.007 - 20.458) )	/ 2 )
	=	-110.78	/	( (231.79	+	231.549)	/ 2 )
	=	-110.78	/	231.6695
	=	-47.82 %

ORIC Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-153.272	/	( ( (328.906 - 19.539)	+	(302.07 - 21.248) )	/ 2 )
	=	-153.272	/	( ( 309.367	+	280.822 )	/ 2 )
	=	-153.272	/	295.0945
	=	-51.94 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

ORIC Pharmaceuticals (NAS:ORIC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ORIC Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ORIC Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ORIC Pharmaceuticals Inc (NAS:ORIC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080

Website

https://www.oricpharma.com

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Executives

Jacob Chacko	director, officer: President and CEO	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Pratik S Multani	officer: Chief Business Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli	officer: Chief Financial Officer	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Pfizer Inc	10 percent owner	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Column Group Llc	10 percent owner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group Ii Gp, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel	10 percent owner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Angie You	director	C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman	director	5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022